DR. SURRINDER PAUL DANG M.D. NPI 1699755116

NPI Details

DR. Surrinder Paul Dang, M.D. is a hematology and oncology internal medicine in Huntsville, AL with 44 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Surrinder Paul Dang, M.D. NPI is 1699755116. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

1 HOSPITAL DR SW STE 400
HUNTSVILLE, AL
ZIP 35801-495
Phone: (256) 705-4224
Fax: (256) 705-4135

The NPI 1699755116 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, ferric derisomaltose, 10 mg (HCPCS:J1437)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, iron dextran, 50 mg (HCPCS:J1750)
• Magnesium level (HCPCS:83735)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Phosphate level (HCPCS:84100)
• Nephelometry, test method using light (HCPCS:83883)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Red blood count automated, with additional calculations (HCPCS:85046)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Unclassified drugs (HCPCS:J3490)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Protein measurement, serum (HCPCS:84165)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Vitamin d-3 level (HCPCS:82306)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Automated urinalysis test (HCPCS:81003)
• Folic acid level, serum (HCPCS:82746)
• Injection of drug or substance into vein (HCPCS:96374)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Collection of blood sample from implanted device (HCPCS:36591)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free (HCPCS:90674)
• Administration of influenza virus vaccine (HCPCS:G0008)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Telephone medical discussion with physician, 5-10 minutes (HCPCS:99441)
• Alpha-fetoprotein (afp) level, serum (HCPCS:82105)
• Administration of vaccine (HCPCS:90471)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Cholesterol level (HCPCS:82465)

The enumeration date for this NPI number is 1/19/2006 and was last updated on 1/27/2023.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.